Mr. Ronald Baldwin Davis, MD Preventive Medicine - Occupational Medicine Medicare: Not Enrolled in Medicare Practice Location: 2629 E Harry, Wichita, KS 67211 Phone: 316-618-8644 Fax: 316-618-8730 |
News Archive
ThromboGenics NV and co-development partner BioInvent International announce today that the first patient has been dosed in a Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism after total hip surgery.
Nearly 100 colleagues recently joined an online celebration to honor Professor Hava T. Siegelmann of the University of Massachusetts Amherst's College of Information and Computer Sciences (CICS) as she received the rarely awarded Meritorious Public Service Medal from the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense (DoD).
Cytokine PharmaSciences, Inc. today announced the completion of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines.
Despite clear directives outlined in the updated guidelines published by the American College of Rheumatology/National Psoriasis Foundation (ACR/NPF) in 2018, there is limited data regarding medication use in real-world clinical practice and patient medication preferences for the treatment of psoriatic arthritis (PsA).
New research published online in The FASEB Journal suggests that the suppression of thyroid hormone receptor activity locally in the retina protects cone photoreceptor cells in mouse models of human retinal degenerative diseases
› Verified 2 days ago